目的探讨普伐他汀联合普萘洛尔治疗青少年高血压的临床疗效,以及对患者左心室质量指数(LVMI)及血清半乳糖凝集素-3(Gal-3)、和肽素(CPP)水平的影响。方法选取医院2020年6月至2023年1月收治的青少年高血压患者138例,按随机数字表法分为...目的探讨普伐他汀联合普萘洛尔治疗青少年高血压的临床疗效,以及对患者左心室质量指数(LVMI)及血清半乳糖凝集素-3(Gal-3)、和肽素(CPP)水平的影响。方法选取医院2020年6月至2023年1月收治的青少年高血压患者138例,按随机数字表法分为观察组和对照组,各69例。两组患者均予普萘洛尔治疗,观察组患者加用普伐他汀治疗,两组患者均连续治疗6个月。结果观察组的总有效率为94.20%,显著高于对照组的81.16%(P<0.05)。治疗后,两组患者的收缩压(SBP)、舒张压(DBP)、24 h SBP标准差(24 h SSD)、24 h SBP变异系数(24 h SCV)、24 h DBP标准差(24 h DSD)、24 h DBP变异系数(24 h DCV)均显著降低(P<0.05),且观察组均显著低于对照组(P<0.05);两组患者的血清内皮素1(ET-1),Gal-3,CPP水平及LVMI均显著降低(P<0.05),NO水平均显著升高(P<0.05),且观察组变化幅度均显著大于对照组(P<0.05)。观察组与对照组的不良反应发生率相当(10.14%比11.59%,P>0.05)。结论普伐他汀联合普萘洛尔治疗青少年高血压的临床疗效较好,可有效控制患者的血压,改善血管内皮功能,调节Gal-3,CPP水平,逆转左心室肥厚,且安全性较高。展开更多
婴幼儿血管瘤(IH)是儿童最常见的血管肿瘤,口服普萘洛尔作为一线疗法虽有效率高,但停药后复发问题突出,严重影响治疗效果。本文综述口服普萘洛尔治疗婴幼儿血管瘤停药后复发的相关研究,阐述普萘洛尔治疗IH的机制,分析复发影响因素,包括...婴幼儿血管瘤(IH)是儿童最常见的血管肿瘤,口服普萘洛尔作为一线疗法虽有效率高,但停药后复发问题突出,严重影响治疗效果。本文综述口服普萘洛尔治疗婴幼儿血管瘤停药后复发的相关研究,阐述普萘洛尔治疗IH的机制,分析复发影响因素,包括停药后的残余病变、血管瘤分布、类型、治疗起始年龄、停药年龄和方式,而性别和溃疡的影响尚存争议。基于现有证据,建议临床通过高危因素识别、个体化停药方案及长期随访降低复发风险。未来需深入探索复发机制并开发精准预测模型,以优化临床决策。Infantile hemangioma (IH) is the most common vascular tumor in children. Although oral propranolol is an effective first-line therapy, recurrence after discontinuation remains a significant issue, severely impacting treatment outcomes. This paper reviews studies on the recurrence of infantile hemangiomas following the discontinuation of oral propranolol, discusses the mechanisms underlying propranolol’s treatment of IH, and analyzes factors contributing to recurrence. These include residual lesions after treatment cessation, hemangioma distribution and type, age at treatment initiation, as well as the age and method of discontinuation. The roles of gender and ulceration in recurrence remain controversial. Based on the existing evidence, it is recommended that clinical practice incorporate risk factor identification, individualized discontinuation plans, and long-term follow-up to reduce the risk of recurrence. Future research should focus on further exploring the mechanisms of recurrence and developing precise predictive models to optimize clinical decision-making.展开更多
文摘目的探讨普伐他汀联合普萘洛尔治疗青少年高血压的临床疗效,以及对患者左心室质量指数(LVMI)及血清半乳糖凝集素-3(Gal-3)、和肽素(CPP)水平的影响。方法选取医院2020年6月至2023年1月收治的青少年高血压患者138例,按随机数字表法分为观察组和对照组,各69例。两组患者均予普萘洛尔治疗,观察组患者加用普伐他汀治疗,两组患者均连续治疗6个月。结果观察组的总有效率为94.20%,显著高于对照组的81.16%(P<0.05)。治疗后,两组患者的收缩压(SBP)、舒张压(DBP)、24 h SBP标准差(24 h SSD)、24 h SBP变异系数(24 h SCV)、24 h DBP标准差(24 h DSD)、24 h DBP变异系数(24 h DCV)均显著降低(P<0.05),且观察组均显著低于对照组(P<0.05);两组患者的血清内皮素1(ET-1),Gal-3,CPP水平及LVMI均显著降低(P<0.05),NO水平均显著升高(P<0.05),且观察组变化幅度均显著大于对照组(P<0.05)。观察组与对照组的不良反应发生率相当(10.14%比11.59%,P>0.05)。结论普伐他汀联合普萘洛尔治疗青少年高血压的临床疗效较好,可有效控制患者的血压,改善血管内皮功能,调节Gal-3,CPP水平,逆转左心室肥厚,且安全性较高。
文摘婴幼儿血管瘤(IH)是儿童最常见的血管肿瘤,口服普萘洛尔作为一线疗法虽有效率高,但停药后复发问题突出,严重影响治疗效果。本文综述口服普萘洛尔治疗婴幼儿血管瘤停药后复发的相关研究,阐述普萘洛尔治疗IH的机制,分析复发影响因素,包括停药后的残余病变、血管瘤分布、类型、治疗起始年龄、停药年龄和方式,而性别和溃疡的影响尚存争议。基于现有证据,建议临床通过高危因素识别、个体化停药方案及长期随访降低复发风险。未来需深入探索复发机制并开发精准预测模型,以优化临床决策。Infantile hemangioma (IH) is the most common vascular tumor in children. Although oral propranolol is an effective first-line therapy, recurrence after discontinuation remains a significant issue, severely impacting treatment outcomes. This paper reviews studies on the recurrence of infantile hemangiomas following the discontinuation of oral propranolol, discusses the mechanisms underlying propranolol’s treatment of IH, and analyzes factors contributing to recurrence. These include residual lesions after treatment cessation, hemangioma distribution and type, age at treatment initiation, as well as the age and method of discontinuation. The roles of gender and ulceration in recurrence remain controversial. Based on the existing evidence, it is recommended that clinical practice incorporate risk factor identification, individualized discontinuation plans, and long-term follow-up to reduce the risk of recurrence. Future research should focus on further exploring the mechanisms of recurrence and developing precise predictive models to optimize clinical decision-making.
